



Drug Prior Authorization Committee Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
July 18, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 OR WebEx

[* Click HERE for Meeting Documents *](#)

<u>Committee Members Present</u>	<u>MO HealthNet Staff Present</u>	<u>Contractors Present</u>
Chris Brown, RPh. Angeline Stanislaus, MD James Krings, MD, MSc Laura Kingsley, PharmD, Chair Maya Moody, DO, FAAP Morgan Sperry, PharmD Nadim Kanafani, MD, MPH Nicole Tran, PharmD Rashmi Srivastava, MD Ricky Ogden Jr, PharmD	Ambra Stotler-Bauda, Pharmacy Specialist Angela Wilson, Pharmacy Operations Manager Carmen Burton, Pharmacy Support Assistant Connie Sutter, Fiscal Manager Danielle Dodd, Special Counsel Elizabeth Sissom, RN, Clinical Review Nurse Jennifer Colozza, PharmD, Clinical Pharmacist Joshua Moore, PharmD, Director of Pharmacy Katie Affolder, UHSP Pharmacy Student Laurel Gibson, UMKC Pharmacy Student Mark Roaseau, R.Ph., Clinical Pharmacist Nikki Ashley, Pharmacy Program Specialist Olivia Rush, PharmD, Program Integrity Pharmacist Timothy Kling, MD, Acting Medical Director Torey Meloy, Benefit Program Senior Specialist	Amanda Williams, PharmD, RPh, GWT Ashley Lytton, RN, BSN, Wipro Chelsea Pendleton, RN, BSN, Wipro John Crowley, PharmD, BCPS, CPPS, Conduent Karen Powell, PharmD, MS, GWT LeAnna Kirsch, RN, Wipro Lokendra Upadhyay, PharmD, Conduent Lynn Morsches, PharmD, Conduent Mandy Nilges, RN, Wipro Megan Fast, PharmD, GWT Melissa Johnston, Conduent Sandy Kapur, PharmD, GWT Serena Barden, PharmD, BCPS, GWT
<u>Committee Members Absent</u>		
J.K. Sturgeon, PharmD, BCPS		

Others Present:

Amy Aikins

Angela Hailes

Ann Lyons

Brooke Polk

Carson VonAlst

Chris Guenther

Cindy Pennington

Claudia

Claudio Sandoval

Clemice Hurst

Curt Griffith

Dakota Rosenfelt

Dan O'Donnell

Dana Monz

Daphne Ni

DM

E Hyde

Eliaa Malak

Erik Schindler

Erika

Gary Parenteau

Gene McCarty

Heather Fremi

Jamie Tobitt

Jason Enders

Jeff Knappen

Jen Tamburo

Jennifer Golwyn

Jenny Carrell

Jessica

Joe Payne

John Bullard

Jomy Joseph

Kat Khachatourian

Kathy Wang

Keith Gulley

Kelly Ressel

Kevin Mann

Kevin Mann

Kheelan Gopal

Kim Witte

Kimberly Deacon

Kurt Hendrickson

Lauren

Lee Ward

Leslie Zanetti

Lori Howarth

Marc Parker

Mariola Vazquez

Mark Stephens

Mary Shefely

Matt Bradley

Melissa Basil

Michelle Schnarre

Michelle Shirley

Nancy Njuguna

Phil Lohec

Rachel Boyer

Ricki Roberson

Rob Kilo

Ryan Doyle

Sara Hovland

Sean Jones

Steve Patterson

Sunny Hirpara

Suzanne Morgan

Tom Seignious

Tracey Maravilla

<p>Welcome, Announcements and Introductions</p>	<p>Joshua Moore, MHD Pharmacy Director, introduced himself, Jennifer Colozza, MHD's new Clinical Pharmacist, Katie Affolder, UHSP Pharmacy Student, and Laurel Gibson, UMKC Pharmacy Student. Joshua called the meeting to order and facilitated the meeting on behalf of the MHD. He also informed the Committee of Dr. Stinson's resignation from the Committee.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the April meeting.</p> <p>Decision: The Committee voted to accept these approved minutes with minor revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - May 2023 Enrollees and Expenditures - July 2022 – May 2023 Expenditures by Service - FY20 – FY23 Pharmacy Expenditures vs Total Medicaid Expenditures - May 2023 Medicaid Expansion Participants, Expenditures, and Claim Count - FY19 to FY23 Mavyret Expenditures - FY23 Top 10 Drug Classes - CY23 Per User Per Month Drug Claim Reimbursement - FY20 – FY23 Rare Disease Expenditures Per Day - Additional information provided regarding: <ul style="list-style-type: none"> o Automatic Refill Regulation o CGM Utilization o Project Hep Cure o CMS – Diagnosis Code Requirement Comments o High Cost Medications Utilization Increases o Drug Shortages <ul style="list-style-type: none"> ▪ Committee asked about potential EpiPen shortages and how to navigate with the upcoming start of school. It was explained that MHD would make the necessary changes to the PDL if/when a shortage was experienced. o Provider Manual and MHD Website Updates o The American Rescue Plan (ARP) Act of 2021 o Biosimilars – Recent approvals and Pipeline o Albuterol Utilization o Prior Authorization Helpdesk Hours

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Committee for discussion and action. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the new drug recommendations with no revisions.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Committee which included: <ul style="list-style-type: none"> o Ampyra Clinical Edit o Besremi Clinical Edit o C5 Complement Inhibitors Clinical Edit o CAR-T Cell Therapy Clinical Edit o Crysvita Clinical Edit o Duchenne Muscular Dystrophy (DMD) Clinical Edit o Gamifant Clinical Edit o Iron – Injectable Step Therapy Edit o Koselugo Clinical Edit o Luxturna Clinical Edit o Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit <ul style="list-style-type: none"> ▪ Jason Enders with Horizon Neurology provided public comment on Uplizna o Reblozyl Clinical Edit o TIMs, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit o Tolvaptan Clinical Edit o Vyvgart Clinical Edit o Zometa Clinical Edit - No other discussion. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Daybue Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

Enjaymo Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Filspari Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Givlaari Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Joenja Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Synagis Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Committee discussed how this edit might change due to newly approved therapies, vaccines and pipeline therapies. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

Tepezza Clinical Edit

Discussion:

- Joshua Moore introduced the edit for discussion to the Committee.
- No other discussion.
- Curt Griffith with Horizon Therapeutics provided public comment.

Decision: The Committee voted to accept the recommended criteria with no additional revisions.

Preferred Drug List Edit Review	
<p>Preferred Drug Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Committee which included: <ul style="list-style-type: none"> ○ Alpha-Glucosidase Inhibitors ○ Amylin Analogs ○ Biguanides & Combinations ○ Cypropryn-Associated Periodic Syndrome (CAPS) Agents ○ DPP-IV Inhibitors & Combinations ○ Erythropoiesis Stimulating Agents ○ GLP-1 Receptor Agonists & Combination Agents <ul style="list-style-type: none"> ▪ Kat Khachatourian with Novo Nordisk provided public comment on Ozempic ▪ Kat Khachatourian with Novo Nordisk provided public comment on Rybelsus ▪ Committee asked for clarification on supply chain issues of Ozempic – manufacturer expects Fall of 2023 to see supplies level out ▪ Committee discussed adding a diagnosis code requirement to this edit ▪ Committee asked about adherence rates between Ozempic vs Rybelsus ▪ Committee asked about suicidality rates being reported in Europe ○ Insulin, Mixed ○ Insulin, Non-Analogs ○ Insulin, Rapid Acting ○ Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral ○ Meglitinides ○ Methotrexate Agents ○ Psoriasis Agents, Oral ○ Sulfonylureas, Second Generation ○ Thiazolidinediones & Combinations ○ TIMs, IL17 Antibody/IL17 Receptor Antagonists ○ TIMs, IL23 Inhibitors and IL23/IL12 Inhibitors <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p>Atopic Dermatitis Agents, Immunomodulators</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Bleeding Disorders Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Claudio Sandoval with Octapharma provided public comment on Nuwiq. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Colony Stimulating Factors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Growth Hormone Agents, Somatropin</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Tracey Maravilla with Ascendis provided public comment on Skytrofa <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Growth Hormone Releasing Factors, Select Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p>Insulin, Long Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Kat Khachatourian with Novo Nordisk provided public comment on Tresiba. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Multiple Sclerosis Agents, Injectable</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Multiple Sclerosis Agents, Oral</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Psoriasis Agents, Topical</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

SGLT Inhibitors & Combination Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Thrombocytopenia Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
TIMs, IL6 Receptor Inhibitors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
TIMs, Janus Kinase (JAK) Inhibitors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Heather Freml with Abbvie yielded public comment time back for Rinvoq. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
TIMs, Misc. Allergy & Asthma Related Monoclonal Antibodies	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Sunny Hirpara with AstraZeneca provided public comment on Fasenra. - Kheelan Gopal with LEO Pharmacy yielded public comment time back for Adbry. - Brooke Polk with Wash U provided public comment on Dupixent. - Committee discussed the current overall criteria was accurate but might need minor tweaks in the future as we receive provider feedback. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

TIMs, Select Agents	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Sara Hovland with Bristol Myers Squibb yielded public comment time back for Sotyktu. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
TIMs, TNF Inhibitors	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Ann Lyons with Amgen provided public comment on Amjevita. - Ann Lyons with Amgen yielded public comment time back for Enbrel. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Urinary Tract Antispasmodics	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Other Business	
Program Utilization Information – Conduent Update	<p>John Crowley with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Call Center Statistics - Missouri SmartPA POS Transparency Report <ul style="list-style-type: none"> o Materials for the Substance Use Disorders Task Force will be brought to the Committee in October - “Top 25” Drugs by Cost/Claims
Adjournment	<p>Maya Moody motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</p>

NEXT MEETING: Tuesday, October 17, 2023; 615 Howerton Court, Conference Room 202 Jefferson City, MO 65109 and WebEx

Roll Call for July 18, 2023

	<u>Action Item</u>							
<u>Board Member</u>	<u>April Meeting Minutes</u>	<u>New Drug Review</u>	<u>Block Vote for Clinical and Fiscal Edits, No Annual Changes</u>	<u>Block Vote for Clinical and Fiscal Edits, Annual Changes</u>	<u>Block Vote for Preferred Drug List Edits, No Annual Changes</u>	<u>Block Vote for Preferred Drug List Edits, Annual Changes</u>	<u>Closing</u>	<u>Adjournment</u>
Angeline Stanislaus	A	A	Y	SY	Y	Y	SY	Y
Chris Brown	SY	SY	SY	Y	Y	SY	Y	Y
J.K. Sturgeon	A	A	A	A	A	A	A	A
James Krings	AB	Y	Y	Y	Y	Y	Y	Y
Laura Kingsley	Y	Y	Y	Y	Y	Y	Y	Y
Maya Moody	MY	MY	MY	MY	MY	MY	MY	MY
Morgan Sperry	Y	Y	Y	Y	Y	Y	Y	Y
Nadim Kanafani	A	Y	Y	Y	Y	Y	Y	SY
Nicole Tran	Y	Y	Y	Y	Y	Y	Y	Y
Rashmi Srivastava	Y	Y	Y	Y	Y	Y	Y	Y
Ricky Ogden	Y	Y	Y	Y	SY	Y	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain